Genelink P/B
P/B (Price-to-Book Ratio) of Genelink (GNLKQ) as of Aug 12, 2026.
Get this data via API
Financial Data API
P/B
-0.00
Last updated:
P/B (Price-to-Book Ratio) of Genelink is 2026 -0.00 . P/B (Price-to-Book Ratio) of Genelink was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Genelink Stock analysis
What does Genelink do? Genelink Inc is a company specializing in the development and marketing of dietary supplements and health products. It was founded in 1996 by Dr. Alan Darmitzel and is headquartered in Salt Lake City, Utah, USA.
The company's business model is based on personalizing dietary supplements and health promotion products. Genelink uses DNA analysis to determine the specific needs of each customer and manufactures customized dietary supplements and health products based on these results.
Genelink offers a wide range of health products tailored to the needs of each individual. The company has various divisions that offer products such as dietary supplements, skincare products, and weight management products.
Genelink supplies a variety of dietary supplements tailored to the needs of each individual customer. The supplements contain ingredients tailored to each customer's genetic profile. For example, a customer at high risk for heart disease may be offered a dietary supplement with ingredients that can reduce the risk of heart disease.
Genelink also offers a range of skincare products tailored to the individual needs of each customer. The skincare products contain ingredients tailored to each customer's specific needs, such as skin type and age.
The company also offers specialized weight management products tailored to the individual needs of each customer. The products contain ingredients that facilitate weight management and can reduce the risk of weight gain.
In summary, Genelink Inc is a company that offers personalized health solutions. Based on the results of DNA analysis, the company manufactures customized dietary supplements, skincare products, and weight management products. Genelink's products and services are designed to meet the individual needs of each customer and provide a personalized approach to health promotion. Genelink is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genelink stock
On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Genelink since 2006 – with annual values, charts, and detailed analysis.
The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.
P/B = Stock Price / Book Value per Share
To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).
A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Genelink with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
Valuation — Genelink
All Key Metrics — Genelink
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth